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Introduction
Clozapine, an atypical antipsychotic, is primarily used for the treatment of treatment-resistant schizophrenia in most parts of the world (1, 2) . Long-term use of clozapine is associated with improvement in clinical symptoms, measurable social and functional gains, and decreased hospitalization as compared with typical antipsychotic agents (3, 4) . Furthermore, meta-analyses of randomized clinical trials (RCTs) (5, 6 ) and a recent review of effectiveness trials (7) supported the greater efficacy of clozapine among antipsychotics in schizophrenia.
A growing number of reports, however, suggest that clozapine may also have a role in other treatment-resistant psychotic conditions (8) (9) (10) , such as schizoaffective disorder (SAD) and psychotic mood disorders (11) (12) (13) . Furthermore, case reports and retrospective studies suggest that clozapine may be particularly effective in the treatment of medication-resistant unipolar depression and bipolar disorder; some even suggested it is more effective than it is for schizophrenia (12, (14) (15) (16) .
Compared with unipolar depression, bipolar disorder (BD) is a more serious type of mood disorder. BD is a recurrent, potentially disabling, sometimes even fatal psychiatric illness (17) (18) (19) , and the estimated lifetime prevalence of various types of BD is over 2.0% (20, 21) . BD is often associated with high levels of unfavorable outcomes or treatment-resistance (22) (23) (24) . In contrast to schizophrenia, definitions of TRBD vary greatly (17, (25) (26) (27) ). However, a failure to respond to at least two trials of dissimilar treatments, involving an adequate dose and duration, could serve as a conservative definition (28-31).
Although mood disorder (MD) was traditionally considered as a rather rare condition in China, recently-conducted epidemiological studies in the country showed that it is one of the common mental disorders (32, 33), with a 1-month prevalence of 6.1% (32). Unlike other countries, clozapine has been widely used for BD in China despite not having been approved for mood disorders (34-36), and it is indeed one of the most commonly used antipsychotics in the treatment of BD (34, 37, 38) . Some psychiatrists even preferred it as a first-line treatment for (38) (39) (40) . Similar to findings from studies in Western countries, RCTs showed that clozapine was an effective add-on treatment to antidepressants for treatment-resistant depression (41) .
Clozapine was also effective for treatment-resistant mania in a case report (42) and a RCT (43) .
Clozapine is a drug of choice for TRBD in China but the evidence for its use in Western countries remains sparse, and the studies are limited to case reports (44) , open-label trials (11) , and only one RCT with fewer than 20 patients in each group (45) . As China has the largest population on clozapine (46-48), the Chinese experience and studies may be of keen interest to Western psychiatrists (49). So far, no exhaustive systematic review on clozapine for TRBD has been published.
The primary aim of this review was to evaluate the efficacy and safety of clozapine for TRBD.
As previously mentioned, in addition to international databases, we also included Chinese databases that are not usually reviewed in articles written by Western psychiatrists. Particular attention was paid to safety and tolerability, as the potentially severe adverse drug reactions (ADRs) associated with clozapine are commonly a factor discouraging clinicians from prescribing it.
Methods
Before we conducted this systematic review, our protocol of reviewing clozapine use for TRBD was published online (http://www.crd.york.ac.uk/prospero/); the registration number was CRD42013004322 at the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PRISMA provides an evidence-based minimum set of items for reporting in systematic reviews and meta-analyses (50).
Types of studies
All types of trials evaluating the efficacy and safety of clozapine for TRBD were eligible for inclusion. We included RCTs (Table 1) , open-label retrospective studies (Table 2 ) and prospective trials (Table 3) . We excluded meta-analyses and systematic reviews. We also excluded from the comprehensive review the case series and reports since they offer lower level of evidence, and high suspicion of publication biases. However, we included them in Table 4 and provided a brief statement on them for the sake of entirety. The retrospective open study by Nielsen et al. (51) was included in this review (Table 2) , although the sample also included patients with non-TRBD; it was not possible to exclude them. All tables provided details of the contamination of the studies by other diagnoses when it was not possible to separate the patients.
Study selection
We searched PubMed, Embase, and Cochrane Library databases and the Cochrane Controlled Trials Register of clozapine for TRBD. We also searched the Chinese databases (CBM and CNKI databases) using the same key words. The search included all studies published between January 1979 and June 2014, regardless of language. The keywords used for the searches included:
clozapine, bipolar disorder, manic, depression, resistant/resistance/refractory, drug therapy, and trial. The keywords were used in combination with the Boolean operators AND, OR, and NOT. We supplemented the search by using the "related article" function. We also manually searched bibliographies of RCTs, meta-analyses, and systematic reviews for studies that were missed in the initial electronic search (52).
One author (X-BL) independently inspected citations from the searches and identified relevant abstracts. A random 20% of the samples were independently re-inspected by author Y-LT to ensure reliability. When disagreements arose, the full report was acquired for more detailed scrutiny. Full reports of the abstracts meeting the review criteria were obtained and inspected by X-BL. Again, a random 20% of reports were re-inspected by Y-LT in order to ensure reliable selection. Where it was not possible to resolve disagreement by discussion, a third author (C-YW) mediated the decision. If the matter was unresolved, an attempt was made to contact the authors of the original study for clarification (53). Review authors X-BL and Y-LT considered all included studies initially, without seeing comparison data, to judge clinical, methodological and statistical heterogeneity and thereby decide whether each study would be included for meta-analysis or other data synthesis. We then extracted data into standard, simple forms. X-BL extracted data from all included studies. In addition, to ensure reliability, Y-LT independently extracted data from a random sample of these studies, comprising 30% of the total. Again, any disagreement was discussed, decisions documented, and, if necessary, authors of studies were contacted for clarification. Data presented only in graphs and figures was extracted whenever possible, but included only if two authors independently had the same result. We also attempted to contact authors through an open-ended request in order to obtain missing information or for clarification whenever deemed necessary. If studies were multi-center, we extracted data relevant to each component center separately (53).
Data Extraction

Assessment of reporting biases
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. We tried to locate the research protocols of included RCTs. If the protocol was available, outcomes in the protocol and in the published report were compared. If the protocol was not available, outcomes listed in the methods section of the trial report were compared with the actually-reported results (54).
Grading recommendations
We used the grading of recommendations assessment, development, and evaluation (GRADE) system to rate the quality of evidence and strength of recommendations of this system review following the guidelines of the Cochrane Collaboration. GRADE included systematic assessments of all included trials across six main domains for each outcome: limitations of the study design and execution, inconsistency, indirectness, and imprecision of results, publication bias, and large treatment effect. Accordingly, we graded the recommendation for outcome measure of clozapine for BPD as very low, low, moderate, or high (Table 5) . 
Results
The various combinations of the following search "clozapine, bipolar disorder, manic, depression, resistant or resistance, refractory" yielded 342 articles, of which 15 studies met the criteria. In total, 1044 TRBD patients had received clozapine treatment (Figure 1 ). There were 2 RCTs (Table 1) ; 3 retrospective studies (Table 2) , and 10 open-label perspective trials (Table 3) .
These studies were equally distributed across the years between 1991 and 2012, which indicates that clozapine for TRBD has been a rather long-lasting, clinically important topic for the last 25 years.
It was not possible to conduct a meta-analysis because of the study's heterogeneity including differences in illness phase (mania, depression, or rapid cycling BD), methodology (open-label trial or RCT) and outcome definition (response or remission). Although meta-analysis is a powerful tool for analyzing data (55), confounding inter-study variables that cannot be controlled may violate basic statistical assumptions, making these types of analyses error-prone (56, 57) . Therefore, we only extracted data onto standard, simple forms on a case-by-case basis and reported the efficacy of clozapine for TRBD when available, as well as other descriptive statistics. Compared with efficacy, there was less heterogeneity in ADRs. Therefore, we conducted data synthesis using this term, and all trials with ADR details were included; the percentage of each ADR was computed in this review and presented in Table 6 .
We were unable to locate the protocols for three RCTs; therefore, we assessed the reporting bias by means of comparing outcomes listed in the methods with the results, which indicated that the reported results were approximately consistent with outcomes listed in the methods.
Quality assessment of the included studies based on the GRADE approach showed many limitations of the study designs, no obvious indirectness, imprecision in result reporting and large treatment effect. Based on the above assessments, the quality of evidence presented for each outcome ranged from ''very low'' to ''moderate'' (Table 5) . (Table 1) . Among them, adjunctive clozapine treatment was superior to treatment as usual for TRBD (45) . In addition, clozapine with added lithium was better than clozapine augmented with valproate in rapid-cycling BD (43) .
Clozapine retrospective trials for TRBD
Three clozapine retrospective trials for TRBD were identified ( Table 2) . Two trials described the number and duration of hospitalizations, the number of psychotropic co-medications and hospital visits for medical reasons and for intentional self-harm/overdose as significantly reduced during clozapine treatment (12, 29, 51, 58) . Another retrospective study comparing schizophrenia and psychotic BD patients indicated that the latter had significantly higher response rates to clozapine (12) .
Clozapine open-label prospective trials for TRBD
The 10 clozapine open-label prospective studies for TRBD (Table 3) , included 5 long-term follow-up studies (11, 16, (59) (60) (61) , 4 focused on mania (44, (62) (63) (64) , and another 1 focused on adolescent patients (65) . Studies found that patients on clozapine demonstrated a significant decrease in the Young Mania Rating Scale (YMRS), Hamilton Depression Rating Scale (HDRS), Brief Psychiatric Rating Scale (BPRS), and Clinical Global Impression Scale (CGI) scores (44, 66) ; the presence of suicidal ideation and aggressive behavior at intake predicted greater improvement at endpoint (59, 65) and improvement in social functioning (16) . In addition, they also found that BD patients showed greater clinical improvement than those with schizophrenia in the long-term follow-up (11, 60) .
Clozapine ADRs in TRBD
ADRs were summarized in Table 6 . The prevalences of the most serious ADRs were leukopenia (2%), agranulocytosis (0.3%), and seizure (0.5%). There were no cases of myocarditis.
The most frequent clinically significant ADRs were sedation (12%), constipation (5%), sialorrhea (5%), weight gain (4%), and any kind of pain (2%). Other ADRs with frequency of 0.5-1% were dizziness, diarrhea (1%), leucopenia, transient fever, urinary incontinence, abnormal EEG, tachycardia, orthostatic hypertension, and nausea. Other ADRs are described in Table 6 .
Discussion
This is the first systematic review of clozapine for TRBD summarizing its efficacy and safety.
Our comprehensive systematic review includes 15 studies with a total of 1,044 patients and suggested that clozapine may be an effective therapy, safe and well tolerated. Although we excluded all of the case series and case reports in this comprehensive review, the literature search provided 13 case reports/series using clozapine for TRBD ( Table 4 ). The 13 articles included 5 on mania (42, (70) (71) (72) (73) , 5 on rapid cycling BD (15, (74) (75) (76) (77) ) and 3 on other TRBDs (29, 78, 79) . Overall, almost all cases were treatment-resistant and had a remission after switching to clozapine monotherapy or adding clozapine to other drugs.
Strength of the study
While many patients with BD respond well to conventional medications (including antidepressants, mood stabilizers and antipsychotics), a substantial proportion do not reach satisfactory response (67) (68) (69) . This systematic review showed that clozapine may be an efficacious therapy for TRBD. First, RCTs showed that: (a) clozapine add-on treatment was superior to treatment as usual in mania, and (b) clozapine plus lithium was better than clozapine plus valproate in rapid cycling BD. Second, retrospective studies of clozapine for TRBD indicated that total number and duration of hospitalizations and the number of psychotropic co-medications were significantly reduced during clozapine treatment. Third, in open-label perspective studies, patients with clozapine demonstrated a significant decrease in the YMRS, HDRS, BPRS, and CGI scores, evidenced improvement in social functioning and suicidal ideation and aggressive behavior, and had fewer subsequent affective episodes; furthermore, TRBD patients showed greater clinical improvement than those with schizophrenia in the long-term follow-up in these trials. The current In general, this review found that clozapine for TRBD was safe and well-tolerated (Table 6) .
Sedation, constipation, sialorrhea, weight gain, and pain were the common ADRs, which is consistent with schizophrenia studies (80, 81) , and they were rather mild and tolerable to most patients. Moderate ADRs included dizziness, diarrhea, transient fever, urinary incontinence, abnormal EEG, tachycardia, orthostatic hypertension, and nausea. Rare ADRs were sweating, hyperlipidemia, diabetes type 2, influenza-like syndrome, postprandial regurgitation, ileus, and bradykinesia, which is also comparable with schizophrenia studies (80, 82) . These ADRs were not severe enough to result in drug discontinuation. The ADRs in the metabolic system were obviously low; there is the possibility of a major underreport in the included trials.
Among all the reports, 17 patients had leukopenia (2%), 2 had agranulocytosis (0.2%), and 5 had seizures (0.5%). These figures tend to be lower than averages reported in schizophrenia reviews (83) (84) (85) (86) (87) (88) (89) . We are not sure whether the lower ADR frequency in BPD vs schizophrenia trials is real or an artefact. Greater underreport and different methodologies may contribute to artificially low ADR frequency. Some clozapine ADRs are dose-related; others are not. Doses in BPD trials appear lower than doses in Western schizophrenia studies, but it was not possible to control doses for confounders such as smoking (which induced clozapine metabolism probably by inducing CYP1A2) and racial differences (see the commentary in the limitation section) (64, 87, 89) .
The agranulocytosis risk is still a concern for clinicians, but mandatory blood monitoring has been shown to considerably reduce the incidence of fully developed cases of agranulocytosis (80) . Thus, appropriate management of clozapine ADRs facilitates a maximization of the benefits of clozapine treatment, and physicians and patients alike should be aware that there is a range of benefits to clozapine use that outweighs its risk (80, 90, 91) .
Clozapine treatment was associated with significant improvement in tardive dyskinesia in seven patients (92) (93) (94) ; clozapine may be useful for long-term treatment to lower tardive (93, 95, 96) . Furthermore, once tardive dyskinesia or dystonia is established, clozapine may be useful for both control of the movement disorder and BD (93, 96) .
The major strength of this study is that we also searched Chinese databases in this systematic review, which included all TRBD clozapine trials conducted in China, where clozapine is widely used. Thus, it is the first review to include all trials available without applying any language restrictions. We found clozapine RCTs in monotherapy or combined with other medications versus other treatments in TRBD patients; the comparison treatments included mood stabilizer (97, 98) 
Limitations of the study
A few limitations of the current review need to be acknowledged. First, it was not possible to conduct a meta-analysis because of the study's heterogeneity, including differences in illness phase (mania, depression or rapid cycling BD), methodology (open-label trials or RCTs) and outcome definition (response or remission). This great heterogeneity may violate basic statistical assumptions and make these analyses error-prone. Therefore, we only extracted data onto standard, simple forms on a case-by-case basis and reported the efficacy of clozapine for TRBD when available. Compared with data on efficacy, there was lower heterogeneity with ADR data, therefore data synthesis using ADRs was conducted and the percentage of each ADR was computed (Table 6 ).
Second, most of the clinical trials included here had major methodological problems: although this review included 15 clinical trials, most of them were open-label observational trials; only 2 RCTs were available. There were no obvious reporting biases in the RCTs, but reporting biases in other studies is possible. Furthermore, the GRADE approach showed the quality of the (Table 5) . Therefore, the current review provided limited evidence for clozapine use. However, two strengths of this current review also need to be mentioned: (1) all available trials were included, without applying any language restrictions; and (2) we provided certain supporting evidence by means of reporting the efficacy case-by-case analysis and computing the percentage of each ADR (Table 6 ).
Third, some trials were "contaminated" by some patents with a diagnosis of SAD or schizophrenia; which does not correspond to the population described as the target population of interest (TRBD). In some trials, we could not separate TRBD patients from the others but the tables provide the details of these "contaminated" studies.
A fourth limitation of this review and all the studies reviewed in it is the lack of close attention to clozapine pharmacokinetic issues on dosing. Clozapine dosing is influenced by racial differences, drug-drug interactions and smoking. In 1997, it was already reported that Chinese Approximately 25% of the Chinese population is CYP2C19 PMs.
Studies of adjunctive clozapine treatment in TRBD usually ignore the major differences in clozapine metabolism associated with co-medication. Carbamazepine is a major inducer of clozapine metabolism (113) and it is possible that valproate may be a mild inducer (114).
Fluvoxamine is a major inhibitor of clozapine metabolism (115) and paroxetine and fluoxetine are mild inhibitors (114, 115) . In conclusion, future studies and meta-analysis of clozapine for TRBD will need to pay attention to important pharmacokinetic differences associated with racial differences, co-medication and smoking, which may have major influences on clozapine dosing but at present are ignored in most published articles.
Comparison with other studies
Poon et al. (2012) performed a literature review on TRBD research findings (17) . It provided few promising leads other than the use of clozapine for TRBD mania, which is comparable to our analysis. Their review was limited by: 1) inclusion of only 2 clozapine trials (44, 45), 2) lack of report on clozapine ADRs, and 3) lack of inclusion of Chinese studies which include the larger numbers of patients.
Gitlin et al. (2003) conducted a review on this topic (116). Their review indicated that
combining multiple agents was the commonly used clinical strategy for TRBD; an approach that may be effective for treatment-resistant patients included high-dose thyroid augmentation, clozapine, calcium channel blockers, and electroconvulsive therapy (ECT), which is consistent with our findings. However, only 3 studies of clozapine treatment were included (45, 60, 64) , and none of the Chinese studies were included. Similarly, there was no safety analysis or data synthesis. However, this review only included some trials conducted before 1998, which excluded most trials of clozapine for TRBD. Similarly, there was no safety analysis or data synthesis in this analysis.
Conclusions
TRBD is a complex, often severe and disabling psychiatric disorder and it often poses a therapeutic challenge (17, 118) . This systematic review showed that clozapine monotherapy or its combination with other medications for TRBD may be both safe and effective. Long-term use of 14 clozapine appeared to be associated with improvement in clinical symptoms, measurable social and functional gains, and decreased hospitalization. Constipation, sedation, sialorrhea, weight gain, aches and pain were the common reported ADRs, though none were severe enough to result in drug discontinuation. The percentage of leukocytopenia, agranulocytosis and seizure were lower than in studies of clozapine for schizophrenia, but it cannot be ruled out that they may be contaminated by ADR underreport. Clozapine for TRBD may increase treatment compliance, which may offer additional therapeutic benefits. On the other hand, some patients may have poor adherence or may not be willing to start clozapine treatment due to the required blood collections to avoid agranulocytosis.
This comprehensive review focused on TRBD but future reviews need to focus on the role of clozapine for the treatment of BD in general. Though clozapine is rarely used for non-treatment-resistant BD elsewhere in the world, emerging evidence from China is encouraging (41, 97, 98) . Since the early 1980s, few clozapine RCTs for BD in general have been published; once more clozapine RCTs are published, a meta-analysis on this important topic will provide clinicians with more choices when treating patients with all kinds of BD, including those with non-treatment-resistant forms.
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